The FDA granted orphan designation to Karyopharm’s padnarsertib as a treatment of soft tissue sarcoma, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI: